Experts in Metabolite
Synthesis, Purification and Natural Products
Supporting pharmaceutical and agrochemical companies globally
Your trusted partner in pharmaceutical and agrochemical R&D
What we do
Hypha Discovery is a specialist CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and late-stage derivatives of drugs and agrochemicals in discovery and development.
We are experts in the scalable synthesis, purification and identification of drug metabolites and oxidised derivatives of lead compounds, and also possess a wealth of experience in the production, purification and structure elucidation of natural products.
Solutions for metabolite synthesis
Hypha Discovery offer a comprehensive suite of techniques for provision of even the most difficult-to-synthesise metabolite, comprising chemical synthesis, recombinant enzymes such as PolyCYPs, microbial biotransformation, mammalian liver fractions as well as the purification of metabolites from biological matrices. We are also experts in the structure elucidation of metabolites by NMR spectroscopy
PolyCYPs+ screening kits comprise 18 PolyCYP isoforms together with the addition of other phase 1 enzymes. Human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3) are included in the kit, with the other human FMO isoforms, available separately at Hypha.
Inclusion of multiple PolyCYPs isoforms broadens coverage of reactions, and which have been proven to produce human and other mammalian CYP-derived metabolites including multi-step metabolites and metabolites of low turnover drugs.
Simple, Effective, Scalable
Produce CYP, AOX & FMO metabolites
Generate multiple hydroxylated and other oxidised derivatives of lead compounds in parallel
Delivering a first class service to our clients worldwide
We look forward to engaging Hypha in the future because their team is professional, and their services complement our internal synthetic efforts for delivering new molecules.
Hypha Discovery News
Hypha’s Q2 2022 newsletter features synthesis of GSH conjugates using PolyCYPs enzymes, metabolite purification case studies, and information on our late-stage oxidation kits.
Hypha’s new service for accessing API degradation products and impurities is featured in our Q1 2022 newsletter. Also highlighted is the CYP active site engineering our Recombinant Technologies Team have undertaken to further develop PolyCYPs enzymes.
In our Q4 2021 technical newsletter we describe how Hypha used PolyCYPs to help the Open Source Antibiotics team identify a drug metabolite.
Stay up to date with the latest news from Hypha Discovery
Sign up for our Newsletter to receive interesting updates and scientific case studies about Hypha’s metabolite generation capabilities and lead optimization solutions
Meet us at one of the conferences we’ll be attending this year.
Read about our publications in the fields of metabolite synthesis, biotransformation and natural products chemistry
Access brochures on drug metabolite synthesis, Hypha’s one-stop metabolite shop and the PolyCYPs platform
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.